OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Hematology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Monocyte or white blood cell counts and β₂ microglobulin predict the durable efficacy of daratumumab with lenalidomide	26
Prognostic impact of IL7R mutations on acute myeloid leukemia	26
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis	25
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges	25
Association between haploidentical hematopoietic stem cell transplantation combined with an umbilical cord blood unit and graft-versus-host disease in pediatric patients with acquired severe ap	24
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study	23
Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–match	20
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine	19
Total body irradiation-based myeloablative conditioning for acute lymphoblastic leukaemia patients undergoing allogeneic haematopoietic stem cell transplantation: the best way to prevent relapse in a	19
Assessment of risk factors for acute graft-versus-host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-eff	18
Supporting leukemia patients in the Philippines: a call to action	18
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment	18
Using T-lymphocyte subsets at engraftment to predict the risk of acute graft-versus-host disease in patients with thalassemia major: development of a new predictive nomogram	15
Between Charybdis and Scylla—an Odyssey in AL amyloidosis: insights and learnings from a narrative review and case report series	14
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study	13
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies	13
Brain iron content and cognitive function in patients with β-thalassemia	12
Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality	12
Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report	12
Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia	11
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from	11
Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers	11
The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study	11
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION)	10
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib	10

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors	9
A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient	9
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis	9
Down syndrome-associated leukaemias: current evidence and challenges	9
A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients	9
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria	8
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma	8
Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase	8
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia	8
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy	8
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia	8
An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report	8
Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments	8
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis	8
Systematic literature review of the indirect costs and humanistic burden of β-thalassemia	8
Rapid and sustained response to luspatercept and eltrombopag combined treatment in one case of clonal cytopenias of undetermined significance with prior failure to cyclosporin and androgen therapy: a	7
Successful treatment of hemophagocytic intravascular large B-cell lymphoma with CNS involvement with BTK inhibitor combined with rituximab and high-dose methotrexate	7
Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation	7
Intensive chemotherapy with dual induction and ALL-like consolidation for childhood acute myeloid leukemia: a respective report from multiple centers in China	7
Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy	6
Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study	6
Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group	6
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia	6
Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia	6
Macrofocal multiple myeloma in the era of novel agents in China	6
Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses	6
Role of abatacept in the prevention of graft-versus-host disease: current perspectives	6
Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China	6